Results 231 to 240 of about 10,191,051 (291)

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

open access: yesPediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz   +7 more
wiley   +1 more source

Perinatal and Early-Life Exposures and Risk of Non-Hodgkin Lymphoma. [PDF]

open access: yesCancers (Basel)
Cholack GA   +14 more
europepmc   +1 more source

Evaluating the Readability of Patient‐Facing Online Educational Materials for Pediatric Leukemia and Lymphoma

open access: yesPediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
ABSTRACT Background Together, leukemia and lymphoma account for 38.7% of newly diagnosed pediatric cancer cases in the United States each year. Many caregivers utilize online resources to inform medical health decisions. Understanding the readability of these materials is critical to ensuring comprehensible patient education.
Chloe Strege   +6 more
wiley   +1 more source

A Novel Case of Sarcoidosis-Lymphoma Syndrome. [PDF]

open access: yesCase Rep Gastrointest Med
Tavakoli M, Pan A, Papasotiriou S.
europepmc   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, Volume 78, Issue 10, Page 1449-1466, October 2026.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Cardiovascular Toxicity Associated With Bispecific Antibodies in Hematological Malignancies: A Comprehensive Pharmacovigilance Analysis

open access: yesAmerican Journal of Hematology, Volume 101, Issue 10, Page 2546-2556, October 2026.
ABSTRACT Cardiovascular adverse events (CVAEs) associated with bispecific T‐cell engaging antibodies (BsAbs) have not been systematically investigated across approved agents. In this disproportionality analysis of FAERS (December 2014–September 2025), reports listing BsAbs as the primary suspected drug (n = 7647) were compared with all other drugs in ...
Malak Munir   +9 more
wiley   +1 more source

Survival of U.S. Military Service Members with Hodgkin Lymphoma by Post-9/11 Deployment Status. [PDF]

open access: yesCancer Res Commun
Gibson S   +8 more
europepmc   +1 more source

Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant

open access: yes
Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
Matthew R. Schuelke   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy